Parthanatos In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Parthanatos is a form of regulated cell death driven by the hyperactivation of [poly(ADP-ribose) polymerase 1 (PARP-1)], leading to catastrophic [NAD+] depletion, accumulation of poly(ADP-ribose) (PAR) polymers, mitochondrial release of apoptosis-inducing factor (AIF), and ultimately large-scale DNA fragmentation. The term "parthanatos" derives from "PAR" (poly ADP-ribose) and "thanatos" (Greek for death), reflecting the central role of PAR polymer signaling in this death pathway. First characterized as a distinct cell death mechanism by Bhatt et al. (2020) and Wang et al. (2009), parthanatos is mechanistically distinct from apoptosis, necroptosis, ferroptosis, and pyroptosis — it is caspase-independent, does not involve the classic apoptotic bodies or membrane blebbing, and proceeds through a unique PARP-1→PAR→AIF→MIF signaling axis.
Parthanatos has emerged as a significant contributor to neuronal loss in Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), and [ischemic stroke], making the PARP-1 pathway an increasingly attractive therapeutic target in neurodegeneration research1.
¶ Step 1: DNA Damage and PARP-1 Hyperactivation
The parthanatos cascade is initiated by extensive DNA damage, which can arise from multiple sources relevant to neurodegeneration:
- oxidative stress: Reactive oxygen species (ROS generated by mitochondrial dysfunction cause single-strand and double-strand DNA breaks, the primary trigger for PARP-1 activation.
- excitotoxicity: Excessive glutamate receptor activation produces nitric oxide (NO) and peroxynitrite (ONOO⁻), which damage DNA and hyperactivate PARP-1.
- Alkylating agents: Environmental toxins such as MNNG (N-methyl-N'-nitro-N-nitrosoguanidine) can directly damage DNA.
- alpha-synuclein pathology: Pathologic alpha-synuclein fibrils activate PARP-1, and PAR polymer production in turn accelerates alpha, creating a feed-forward toxic loop2.
PARP-1, a 116 kDa nuclear enzyme, normally functions as a DNA damage sensor, catalyzing the transfer of ADP-ribose units from [NAD+] to target proteins (PARylation) to recruit DNA repair machinery. Under physiological conditions, PARP-1-mediated PARylation facilitates base excision repair and maintains genomic integrity. However, when DNA damage is extensive, PARP-1 becomes hyperactivated, consuming massive quantities of NAD+ and generating large, branched PAR polymers that exceed the cell's capacity for homeostatic regulation3.
¶ Step 2: NAD+ and ATP Depletion
PARP-1 hyperactivation leads to rapid and profound depletion of cellular NAD+ pools. Since NAD+ is essential for glycolysis (as a cofactor for glyceraldehyde-3-phosphate dehydrogenase) and [mitochondrial] oxidative phosphorylation, its depletion triggers a catastrophic bioenergetic crisis:
- NAD+ consumption: Each ADP-ribose unit added to PAR chains consumes one molecule of NAD+. A single hyperactivated PARP-1 molecule can consume thousands of NAD+ molecules within minutes.
- ATP collapse: NAD+ depletion halts glycolysis, and attempts to resynthesize NAD+ via the NAD+ salvage pathway consume additional ATP. The resulting energy failure compromises all ATP-dependent cellular processes4.
- [Metabolic reprogramming]: Cells attempt to compensate via the hexose monophosphate shunt, but this pathway is insufficient to prevent bioenergetic catastrophe.
While NAD+ and ATP depletion contribute to cell death, they are necessary but not sufficient for parthanatos — the critical executioner step requires PAR polymer signaling to mitochondria.
The PAR polymer itself acts as a death signal. Free PAR polymers (cleaved from PARylated proteins by poly(ADP-ribose) glycohydrolase, PARG) translocate from the nucleus to the cytoplasm, where they interact with the outer mitochondrial membrane:
- PAR binding to AIF: PAR polymers bind directly to apoptosis-inducing factor (AIF), a flavoprotein oxidoreductase normally tethered to the inner mitochondrial membrane. PAR binding induces a conformational change in AIF that promotes its release5.
- Mitochondrial permeability transition: PAR binding may also depolarize mitochondria and promote opening of the mitochondrial permeability transition pore (mPTP), facilitating AIF release.
- AIF cleavage: Calpains and cathepsins cleave the 67 kDa mature AIF from its mitochondrial anchor, generating a soluble 57 kDa truncated AIF (tAIF) that translocates to the cytoplasm.
¶ Step 4: AIF-MIF Nuclear Translocation and DNA Fragmentation
Released AIF translocates to the nucleus, but AIF itself lacks intrinsic nuclease activity. The critical executioner of parthanatos is macrophage migration inhibitory factor (MIF):
- AIF-MIF complex formation: In the cytoplasm, tAIF recruits MIF (a 12.5 kDa protein with cryptic nuclease activity), forming an AIF-MIF complex.
- Nuclear import: The AIF-MIF complex enters the nucleus, where MIF functions as a DNA nuclease, cleaving genomic DNA into large fragments (~50 kb) — a signature distinct from the internucleosomal DNA laddering seen in apoptosis6.
- Chromatinolysis: MIF-dependent endonuclease activity produces large-scale chromatin condensation and fragmentation, an irreversible commitment point that ensures cell death.
This step was definitively established by Wang et al. (2016), who demonstrated that genetic ablation of MIF nuclease activity prevented parthanatos without affecting AIF nuclear translocation.
In Alzheimer's disease, multiple pathological features converge to activate parthanatos:
- Amyloid-Beta toxicity: Aβ oligomers induce oxidative stress and DNA damage in neurons, activating PARP-1. Brains from AD patients show elevated levels of PAR polymers and PARP-1 activity compared to age-matched controls7.
- Tau(/proteins/tau pathology: Hyperphosphorylated tau] disrupts [mitochondrial] function and increases oxidative DNA damage, further promoting PARP-1 hyperactivation.
- NAD+ depletion: AD brains show reduced NAD+ levels, consistent with chronic PARP-1 overactivation. This intersects with age-related decline in [NAD+ metabolism].
- PARP-1 activation correlates with disease severity: Post-mortem studies demonstrate that nuclear PAR accumulation increases with Braak staging, suggesting parthanatos contributes to progressive neuronal loss.
The parthanatos pathway is particularly relevant to Parkinson's disease:
- alpha-synuclein–PARP-1 feed-forward loop: Pathologic alpha-synuclein fibrils activate PARP-1, and the resulting PAR polymers accelerate alpha-synuclein fibrillization and cell-to-cell propagation. This bidirectional relationship was demonstrated by Kam et al. (2018), establishing parthanatos as a key contributor to dopaminergic neurodegeneration2.
- Dopaminergic neuron vulnerability: The high oxidative metabolic load and dopamine auto-oxidation in substantia nigra pars compacta neurons generate persistent DNA damage, making these cells particularly susceptible to PARP-1 hyperactivation.
- MPTP/MPP+ models: The classic Parkinson's toxin MPTP induces PARP-1 activation and parthanatos in dopaminergic neurons. PARP-1 knockout mice are resistant to MPTP-induced neuronal loss.
Huntington's disease involves parthanatos through:
- Mutant huntingtin toxicity: The expanded polyglutamine repeat in huntingtin causes transcriptional dysregulation and oxidative stress, both of which activate PARP-1.
- Medium spiny neuron vulnerability: Striatal neurons show elevated PARP-1 activity and PAR accumulation in HD models.
- PARP-1 inhibition is neuroprotective: Genetic deletion or pharmacological inhibition of PARP-1 reduces neurodegeneration in multiple HD mouse models8.
In ALS:
- SOD1 mutations: Mutant SOD1 increases oxidative stress and DNA damage in motor neurons, activating PARP-1.
- TDP-43 pathology: TDP-43 mislocalization and aggregation are associated with DNA damage response activation and PARP-1 hyperactivation.
- Motor neuron selectivity: The high metabolic demands and long axonal projections of motor neurons make them particularly vulnerable to NAD+ depletion-driven bioenergetic failure9.
Although not a neurodegenerative disease per se, ischemic stroke involves massive parthanatos:
- Ischemia-reperfusion injury: Restoration of blood flow after ischemia generates a burst of ROS causing extensive DNA damage and PARP-1 hyperactivation.
- Excitotoxic cascade: Glutamate release during ischemia activates NMDA receptor] receptors, producing NO and peroxynitrite that damage DNA.
- PARP-1 knockout protection: PARP-1⁻/⁻ mice show >80% reduction in infarct volume after experimental stroke, demonstrating the dominance of parthanatos in acute ischemic neuronal death10.
Parthanatos intersects with but remains distinct from other regulated cell death pathways in neurodegeneration:
| Feature |
Parthanatos |
apoptosis |
necroptosis |
ferroptosis |
Pyroptosis |
| Key mediator |
PARP-1/PAR/AIF/MIF |
Caspases |
RIPK1/RIPK3/MLKL |
Iron/lipid peroxidation |
Caspase-1/GSDMD |
| Caspase-dependent |
No |
Yes |
No |
No |
Yes |
| DNA fragmentation |
Large fragments (~50 kb) |
Internucleosomal ladder |
Variable |
Minimal |
Minimal |
| Morphology |
Nuclear shrinkage, chromatinolysis |
Apoptotic bodies |
Membrane rupture, swelling |
Membrane lipid damage |
Membrane pores, swelling |
| Inflammation |
Moderate (DAMP release) |
Low |
High |
Moderate |
High |
| NAD+ depletion |
Yes (primary) |
No |
No |
No |
No |
Notably, parthanatos can occur simultaneously with other death pathways, and cells may shift between pathways depending on the severity and nature of the insult. [Calpain]-dependent AIF cleavage represents a convergence point with calcium-dependent cell death mechanisms11.
PARP inhibitors, originally developed for oncology (e.g., olaparib, veliparib, niraparib), are being investigated for neuroprotection:
- First-generation inhibitors (3-aminobenzamide): Demonstrated proof-of-concept neuroprotection in stroke and PD models but lacked CNS penetrance and specificity.
- Clinical PARP inhibitors: Olaparib, veliparib, and talazoparib show neuroprotective effects in preclinical models but were designed for cancer and may have unfavorable CNS pharmacokinetics.
- CNS-optimized PARP inhibitors: Next-generation molecules with improved Blood-Brain Barrier penetrance are under development for neurodegenerative applications12.
Boosting NAD+ levels can counteract PARP-1-mediated NAD+ depletion:
- Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN): NAD+ precursors that increase cellular NAD+ pools, potentially offsetting PARP-1-mediated consumption. Clinical trials are underway for AD and PD.
- NAD+ biosynthesis activators: Compounds that upregulate NAMPT (the rate-limiting enzyme in the NAD+ salvage pathway) may provide sustained NAD+ replenishment.
- AIF inhibitors: Compounds that block AIF release or nuclear translocation could prevent the executioner phase of parthanatos without affecting PARP-1's beneficial DNA repair functions.
- MIF nuclease inhibitors: Targeting MIF's endonuclease activity specifically blocks the final irreversible step. Wang et al. (2016) demonstrated that mutating MIF's nuclease active site prevented parthanatos-mediated neuronal death6.
- PAR degradation enhancement: Upregulating PARG (PAR glycohydrolase) or ARH3 (ADP-ribosylhydrolase 3) to accelerate PAR polymer degradation could reduce AIF release.
¶ Biomarkers and Detection
Detection of parthanatos in clinical and experimental settings relies on:
- PAR polymer levels: Elevated PAR in cerebrospinal fluid (CSF) or brain tissue indicates PARP-1 hyperactivation. PAR immunostaining is the gold standard for confirming parthanatos in post-mortem tissue.
- AIF nuclear translocation: Immunofluorescence demonstrating AIF redistribution from mitochondria to the nucleus.
- NAD+ depletion: Metabolomic measurement of NAD+/NADH ratios in affected tissues or biofluids.
- Large-scale DNA fragmentation: Pulsed-field gel electrophoresis showing ~50 kb DNA fragments (distinct from the ~180 bp apoptotic ladder).
The study of Parthanatos In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Fatokun, A. A., Dawson, V. L., & Dawson, T. M. (2014). Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. British Journal of Pharmacology, 171(8), 2000-2016. DOI
- [Kam, T. I., Mao, X., Park, H., et al. (2018). Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson's Disease. Science, 362(6414), eaat8407. DOI
- [Andrabi, S. A., Umanah, G. K., Chang, C., et al. (2014). Poly(ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proceedings of the National Academy of Sciences, 111(28), 10209-10214. DOI
- [Bai, P., & Cantó, C. (2012). The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metabolism, 16(3), 290-295. DOI
- [Yu, S. W., Wang, H., Poitras, M. F., et al. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science, 297(5579), 259-263. DOI
- [Wang, Y., An, R., Umanah, G. K., et al. (2016). A nuclease that mediates cell death induced by DNA damage and poly(ADP-ribose) polymerase-1. Science, 354(6308), aad6872. DOI
- [Love, S., Barber, R., & Wilcock, G. K. (1999). Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's Disease. Brain, 122(2), 247-253. DOI
- [Vis, J. C., Schiber, N., de Boer-van Huizen, R. T., et al. (2005). Expression pattern of apoptosis-related markers in Huntington's Disease. Acta Neuropathologica, 109(3), 321-328. DOI
- [McGurk, L., Gomes, E., Guo, L., et al. (2018). Poly(ADP-ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Molecular Cell, 71(5), 703-717. DOI
- [Eliasson, M. J., Sampei, K., Mandir, A. S., et al. (1997). Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nature Medicine, 3(10), 1089-1095. DOI
- [Park, H., Kam, T. I., Dawson, T. M., & Dawson, V. L. (2020). Poly (ADP-ribose) (PAR)-dependent cell death in neurodegenerative diseases. International Review of Cell and Molecular Biology, 353, 1-29. DOI
- [Mao, K., & Zhang, G. (2022). The role of PARP1 in neurodegenerative diseases and aging. The FEBS Journal, 289(8), 2013-2024. DOI
🟡 Moderate Confidence
| Dimension |
Score |
| Supporting Studies |
12 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
67% |
| Mechanistic Completeness |
50% |
Overall Confidence: 44%